Viela Bio (NYSE:VIE) Rating Increased to Buy at Zacks Investment Research

Viela Bio (NYSE:VIE) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Friday, Zacks.com reports. The firm presently has a $43.00 price objective on the stock. Zacks Investment Research‘s target price would indicate a potential upside of 14.39% from the company’s current price.

According to Zacks, “Viela Bio Inc. is a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases. Viela Bio Inc. is headquartered in Gaithersburg, Maryland. “

Other equities research analysts have also recently issued research reports about the company. Goldman Sachs Group began coverage on Viela Bio in a report on Monday, October 28th. They issued a “buy” rating and a $32.00 price target on the stock. Cowen began coverage on Viela Bio in a report on Monday, October 28th. They issued an “outperform” rating on the stock. Guggenheim began coverage on Viela Bio in a report on Monday, October 28th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, Morgan Stanley upped their price target on Viela Bio from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average price target of $38.50.

Shares of VIE traded up $2.01 on Friday, reaching $37.59. The stock had a trading volume of 1,959 shares, compared to its average volume of 107,067. The company’s 50-day moving average is $30.21. Viela Bio has a twelve month low of $18.20 and a twelve month high of $47.79.

Viela Bio (NYSE:VIE) last released its quarterly earnings results on Thursday, November 14th. The company reported ($65.00) earnings per share for the quarter.

Viela Bio Company Profile

Viela Bio, Inc, a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company is developing inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder; kidney transplant desensitization; myasthenia gravis; and IgG4-related diseases.

See Also: Why are percentage decliners important?

Get a free copy of the Zacks research report on Viela Bio (VIE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viela Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viela Bio and related companies with MarketBeat.com's FREE daily email newsletter.